NY-ESO-1 expression in DCIS: A new predictor of good prognosis

File Description SizeFormat 
348.pdfPublished version375.27 kBAdobe PDFView/Open
Title: NY-ESO-1 expression in DCIS: A new predictor of good prognosis
Authors: Coombes, RC
Caballero, OL
Shousha, S
Ghaem-Maghami, S
Woodley-Barker, L
Wilhelm-Benartzi, CS
Neville, AM
Item Type: Journal Article
Abstract: BACKGROUND: At present, it is difficult to predict which patients with ductal carcinoma-in-situ (DCIS) will subsequently develop frank invasive breast cancer (IDC). A recent survey by our group has shown that NY-ESO-1 and MAGEA are both expressed in DCIS. This study was aimed at determining whether expression of these antigens was related to the later development of IDC. RESULTS: 14 of 42 (33%) of patients developed invasive breast cancer during the follow up period. Only one of those DCIS cases that relapsed was positive for NYESO-1 at diagnosis. In contrast, DCIS samples of 15 of the 28 (54%) of those patients who remained disease-free expressed NY-ESO-1. (Permutation chi square p=0.0033). METHODS: We identified 42 patients with DCIS, and followed them up for more than 10 years. NY-ESO-1 and MAGEA were demonstrated by immunostaining as were CD8+ infiltrates on all sections together with the conventional markers, ER, PR, and HER2. CONCLUSIONS: Expression of NY-ESO-1 may predict those patients who will not subsequently develop invasive breast cancer and could therefore potentially be helpful in defining prognosis in patients with DCIS.
Issue Date: 5-Apr-2017
Date of Acceptance: 25-Mar-2017
URI: http://hdl.handle.net/10044/1/49520
DOI: https://dx.doi.org/10.18632/oncoscience.348
ISSN: 2331-4737
Publisher: Impact Journals
Start Page: 33
End Page: 40
Journal / Book Title: Oncoscience
Volume: 4
Issue: 3-4
Copyright Statement: © 2017 Coombes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords: CT antigen
breast cancer
ductal-carcinoma-in-situ (DCIS)
immunotherapy
prognosis
CT antigen
breast cancer
ductal-carcinoma-in-situ (DCIS)
immunotherapy
prognosis
Publication Status: Published
Conference Place: United States
Appears in Collections:Division of Surgery
Department of Medicine
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx